Yan Tan

发表

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

A. Hui, W. Xue, Kexin Li, 2022, Neurology and Therapy.

Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.

A. Hui, G. Wei, Kexin Li, 2022, Pulmonary pharmacology & therapeutics.

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation study

A. Hui, Bo Yang, G. Wei, 2021 .

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis

A. Hui, L. Zuo, Q. Zheng, 2022, European Journal of Clinical Pharmacology.

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.

A. Hui, Lei Diao, Yu Jiang, 2022, European journal of cancer.

Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males

Jiangfan Li, Lei Diao, Kexin Li, 2023, Advances in Therapy.

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease

A. Hui, L. Zuo, G. Wei, 2022, Drugs in R&D.

A vehicle tracking algorithm combining detector and tracker

Bo Yang, Gang Wang, Yan Tan, 2020, EURASIP J. Image Video Process..

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics

Xin Huang, Lei Diao, Chao Li, 2023, Frontiers in Pharmacology.

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

A. Hui, Xin Huang, K. Zeng, 2023, BMC Medicine.